Cargando…

Peritoneal trauma releases CA125?

Detalles Bibliográficos
Autores principales:	Redman, C. W., Jones, S. R., Luesley, D. M., Nicholl, S. E., Kelly, K., Buxton, E. J., Chan, K. K., Blackledge, G. R.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1988
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246796/ https://www.ncbi.nlm.nih.gov/pubmed/3207605

Ejemplares similares

Single agent high-dose cisplatin (200 mg m-2) treatment in ovarian carcinoma.
por: Kehoe, S., et al.
Publicado: (1992)

Tumour cell activity markers in epithelial ovarian cancer: are biochemical and cytometric indices complementary?
por: Redman, C. W., et al.
Publicado: (1990)

Peritoneal Tuberculosis With Raised Cancer Antigen 125 (CA-125) in a Post-partum Woman: A Case Report
por: Mahajan, Mayank, et al.
Publicado: (2023)

Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis
por: Panorchan, Kwanpeemai, et al.
Publicado: (2014)

The relationship between effluent potassium due to cellular release, free water transport and CA125 in peritoneal dialysis patients
por: Coester, Annemieke M., et al.
Publicado: (2008)

TB Peritonitis Mistaken for Ovarian Carcinomatosis Based on an Elevated CA-125
por: Boss, Joseph D., et al.
Publicado: (2012)

Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials.
por: Warwick, J., et al.
Publicado: (1995)

CA-125 concentration in serum and peritoneal fluid in patients with endometriosis – preliminary results
por: Szubert, Maria, et al.
Publicado: (2012)

CA-125 and CCL2 may indicate inflammation in peritoneal dialysis patients
por: de Oliveira, Wander Valadares, et al.
Publicado: (2021)

Peritoneal tuberculosis with elevated CA-125 mimicking ovarian cancer with carcinomatosis peritonei: Crucial CT findings
por: Chien, Jerry Chin-Wei, et al.
Publicado: (2016)

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.
por: Blackledge, G., et al.
Publicado: (1989)

Serum CA125 a potential marker of volume status for peritoneal dialysis patients?
por: Wijayaratne, Dilushi, et al.
Publicado: (2021)

The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.
por: Hawkins, R. E., et al.
Publicado: (1989)

Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women
por: Huang, Chi-Jung, et al.
Publicado: (2016)

Clinical Significance of Serum CA125, CA19-9, CA72-4, and Fibrinogen-to-Lymphocyte Ratio in Gastric Cancer With Peritoneal Dissemination
por: Huang, Chao, et al.
Publicado: (2019)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

Expression of CA125 in pancreatic carcinoma and chronic pancreatitis.
por: Macdonald, F., et al.
Publicado: (1988)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

Principles and Innovations in Peritoneal Surface Malignancy Treatment
por: MacArthur, Kelly M., et al.
Publicado: (2013)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

Utility of Preoperative CA125 Assay in the Management Planning of Women Diagnosed with Uterine Cancer
por: Povolotskaya, N., et al.
Publicado: (2014)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

Exploring the Glycosylation of Serum CA125
por: Saldova, Radka, et al.
Publicado: (2013)

CA125 effects on humoral immunosuppression
por: Kline, J. Bradford, et al.
Publicado: (2017)

Carbohydrate antigen 125 and carcinoembryonic antigen in the differentiation of tuberculous peritonitis and peritonitis carcinomatosa
por: Tong, Huan, et al.
Publicado: (2017)

CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies
por: Deng, Lin, et al.
Publicado: (2020)

Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer
por: Jin, Xiayu, et al.
Publicado: (2022)

CA-125 is not a useful marker in metastatic breast cancer.
por: Seckl, M. J., et al.
Publicado: (1992)

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
por: Menon, U, et al.
Publicado: (1999)

Oncological markers CA-125, CA 19-9 and endometriosis
por: Fiala, Ludek, et al.
Publicado: (2018)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features
por: Barr, Chloe E., et al.
Publicado: (2022)

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
por: Dunton, Charles J., et al.
Publicado: (2021)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.
por: Fisken, J., et al.
Publicado: (1993)

Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?
por: Jäger, W., et al.
Publicado: (1994)

Clinical utility of CA-125 in the management of uterine carcinosarcoma
por: Matsuo, Koji, et al.
Publicado: (2018)

Massive Elevation of CA-125 in Chylous Ascites
por: Orbay, Tuğçe Merve, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b9i7rclc0eht7m1njb01dqts6c